[HTML][HTML] The role of brain radiotherapy before first-line afatinib therapy, compared to gefitinib or erlotinib, in patients with EGFR-mutant non-small cell lung cancer
HA Jung, S Park, SH Lee, JS Ahn… - Cancer research and …, 2022 - synapse.koreamed.org
Purpose Brain metastasis is common in patients with epidermal growth factor receptor
(EGFR)–mutant non–small cell lung cancer (NSCLC) at initial presentation. A previous study …
(EGFR)–mutant non–small cell lung cancer (NSCLC) at initial presentation. A previous study …
A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis …
L Cai, J Zhu, X Zhang, S Lin, X Su, P Lin, K Chen… - Journal of neuro …, 2014 - Springer
We proposed to identify the efficacy of an epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) using whole brain radiotherapy (WBRT)/stereotactic radiosurgery …
kinase inhibitor (TKI) using whole brain radiotherapy (WBRT)/stereotactic radiosurgery …
CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives
LA Berger, H Riesenberg, C Bokemeyer… - Lung Cancer, 2013 - Elsevier
A considerable proportion of non-small-cell lung cancer (NSCLC) patients will develop
central nervous system (CNS) metastases throughout the course of their disease and these …
central nervous system (CNS) metastases throughout the course of their disease and these …
EGFR mutation status on brain metastases from non-small cell lung cancer
F Hsu, A De Caluwe, D Anderson, A Nichol, T Toriumi… - Lung Cancer, 2016 - Elsevier
Objectives The purpose of this study was to examine the impact of EGFR mutations on the
incidence of brain metastases in patients with advanced non-small cell lung cancer …
incidence of brain metastases in patients with advanced non-small cell lung cancer …
Impact of deferring radiation therapy in patients with epidermal growth factor receptor–mutant non-small cell lung cancer who develop brain metastases
WJ Magnuson, JT Yeung, PD Guillod… - International Journal of …, 2016 - Elsevier
Purpose To perform a retrospective analysis of patients with epidermal growth factor
receptor (EGFR)-mutant lung adenocarcinoma who developed brain metastases (BM) to …
receptor (EGFR)-mutant lung adenocarcinoma who developed brain metastases (BM) to …
[HTML][HTML] Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
S Bhandari, N Dunlap, G Kloecker - Journal of Thoracic Disease, 2021 - ncbi.nlm.nih.gov
Epidermal growth factor receptor (EGFR) mutations are present in 20–40% of non-small cell
lung cancers (NSCLCs). Brain metastasis (BM) is more common in EGFR-mutated NSCLC …
lung cancers (NSCLCs). Brain metastasis (BM) is more common in EGFR-mutated NSCLC …
Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal …
H Wu, Q Zhang, Y Chen, Y Yang, M Xie, Z Huang, Y Xu… - Lung Cancer, 2024 - Elsevier
Background Leptomeningeal metastasis (LM) is associated with an extremely poor
prognosis in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell …
prognosis in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell …
[HTML][HTML] Real-world data on prognostic factors for overall survival in EGFR-mutant non-small-cell lung cancer patients with brain metastases
X Yu, Y Fan - Journal of Cancer, 2019 - ncbi.nlm.nih.gov
Background: With the wide application of epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …
Role of EGFR inhibitors in the treatment of central nervous system metastases from non-small cell lung cancer
GL Ceresoli - Current Cancer Drug Targets, 2012 - ingentaconnect.com
Brain metastases (BM) are a common occurrence in patients with non-small cell lung cancer
(NSCLC). Standard therapy options include whole brain radiotherapy and, in selected …
(NSCLC). Standard therapy options include whole brain radiotherapy and, in selected …
[HTML][HTML] Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients …
Y Liu, L Deng, X Zhou, Y Gong, Y Xu, L Zhou, J Wan… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) has intracranial
activity in EGFR-mutant Non-Small Cell Lung Cancer (NSCLC). The optimal timing of brain …
activity in EGFR-mutant Non-Small Cell Lung Cancer (NSCLC). The optimal timing of brain …